Document is current
Any future updates will be listed below
-
Authors
Marquard, Jasmine Melissa
Lønborg, Jacob
Obling, Laust Emil Roelsgaard
Beske, Rasmus Paulin
Zhou, Yan
Nepper-Christensen, Lars
Vejlstrup, Niels
Bang, Lia Evi
Hassager, Christian
Folke, Fredrik
Andersen, Lars Bredevang
Christensen, Helle Collatz
Holmvang, Lene
Pedersen, Frants
Ahlehoff, Ole
Jabbari, Reza
Minkkinen, Mikko
Sørensen, Rikke
Tilsted, Hans-Henrik
Engstrøm, Thomas
-
Funding
Funding for this research was provided by:
Copenhagen University
- License Information
-
More Information
Article History
Received: 26 September 2024
Accepted: 8 March 2025
First Online: 18 March 2025
Declarations
:
: Before initiation, the trial was registered at (Unique Identifer: NCT05462730) and approved in the Clinical Trials Information System (EU-CT number: 2022–500762-10–00) and by the Danish Data Protection Agency (ID: P-2022–280), and all patients provided informed consent.
: Not applicable.
: T. Engstrøm has received speaker fees from Abbott Vascular, Boston Scientific, and Bayer, an advisory board fee from Abbott, Novo Nordisk and participated in Data Safety Monitoring of the INFINITY Trial, unrelated to this topic. C. Hassager has received an unrestricted grant from the Lundbeck Foundation, a speaker honorarium from Abiomed, and holds positions as a board member of the European Society of Cardiology. F. Folke has received research grants from the Novo Nordisk Foundation and the Laerdal Foundation. M. Minkkinen has received travel expenses and speaker fee from Abbott and speaker fee and proctoring for Boston Scientific. J. Lønborg has received an advisory board fee, an unrestricted grant, and speakers fee from Boston Scientific and speakers fee from Abbott, unrelated to this topic. All other au-thors have no conflicts of interest to disclose.
